This analysis reveals reduced tumor growth by 86.34% with therapeutic agents in a tumor microenvironment, suggesting ferroptosis may overcome drug resistance.
Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation and redox imbalance, has emerged as a promising strategy for treating drug-resistant cancers. However, its therapeutic efficacy is often limited by the antioxidant-rich tumor microenvironment (TME), which inhibits reactive oxygen species (ROS) accumulation. In this study, we introduced a tumor-responsive nanoplatform (MLCT) designed to synergistically amplify ferroptosis through a combination of iron catalysis, calcium overload, nitric oxide (NO) release, and photothermal stimulation. The MLCT platform consisted of mesoporous polydopamine (MPDA), calcium peroxide (CaO₂), l-arginine (LA), and a tannic acid-Fe³⁺ (TA-Fe) shell, facilitating TME-responsive release of therapeutic agents. In vitro, MLCT effectively depleted glutathione (GSH) and sustained NO generation, resulting in elevated ROS levels and mitochondrial dysfunction. Additionally, upon near-infrared (NIR) irradiation, localized hyperthermia further potentiated ferroptotic activity. In vivo, MLCT combined with NIR treatment resulted in an 86.34% reduction in tumor growth, with minimal systemic toxicity. These results highlighted the potential of MLCT as a precision-engineered ferroptosis platform for enhanced cancer therapy.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: